Enlicitide Decanoate

What is Enlicitide Decanoate?#

Enlicitide decanoate (MK-0616) is a first-in-class oral macrocyclic peptide inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). Developed by Merck, enlicitide represents a breakthrough in cardiovascular medicine by delivering the LDL cholesterol-lowering efficacy of injectable PCSK9 inhibitors through a once-daily oral tablet.

PCSK9 inhibition has been established as one of the most effective approaches to lowering LDL cholesterol beyond what statins alone can achieve. The injectable PCSK9 monoclonal antibodies evolocumab (Repatha) and alirocumab (Praluent) have demonstrated cardiovascular outcomes benefits but have seen limited uptake due to the burden of regular injections, high cost, and patient reluctance toward injectable therapy. Enlicitide addresses these barriers by converting the PCSK9 inhibitor class from injectable to oral.

In the Phase 3 CORALreef Lipids trial published in the New England Journal of Medicine (2026), enlicitide 20 mg once daily achieved a 55.8% placebo-adjusted reduction in LDL cholesterol at 24 weeks, matching the efficacy of injectable PCSK9 antibodies. Merck is expected to submit enlicitide for FDA approval in early 2026.

Mechanism of Action#

PCSK9 is a serine protease that binds to LDL receptors (LDLR) on the surface of hepatocytes, directing them toward lysosomal degradation rather than recycling back to the cell surface. By reducing the number of available LDL receptors, PCSK9 decreases the liver's ability to clear LDL cholesterol from the blood.

Enlicitide is a macrocyclic peptide that binds to the LDLR-binding domain of PCSK9 with high affinity (IC50 = 2.5 nM), preventing PCSK9 from interacting with LDL receptors:

• PCSK9 neutralization: Binds directly to PCSK9, blocking its interaction with LDLR
• LDLR preservation: Allows LDL receptors to be recycled to the hepatocyte surface rather than degraded
• Enhanced LDL clearance: More surface LDL receptors means greater hepatic uptake of LDL cholesterol from circulation
• Broad lipid effects: Also reduces apolipoprotein B, non-HDL cholesterol, and lipoprotein(a)

The mechanism is pharmacologically identical to injectable PCSK9 monoclonal antibodies but achieved through a fundamentally different molecular platform (macrocyclic peptide vs monoclonal antibody).

Clinical Development#

Enlicitide has been evaluated in a comprehensive Phase 2/3 clinical development program:

Phase 2b (JACC 2023)#

Published by Ballantyne et al. (PMID 36889610), this dose-ranging trial tested four doses (6, 12, 18, 30 mg daily) in 381 adults with hypercholesterolemia. LDL-C reductions were dose-dependent, reaching 60.9% with the 30 mg dose at week 8. The 20 mg dose was selected for Phase 3 based on efficacy-safety optimization.

CORALreef Lipids (Phase 3, NEJM 2026)#

The pivotal CORALreef Lipids trial (NCT05952856) randomized 2,909 adults with ASCVD or high ASCVD risk to enlicitide 20 mg daily or placebo across 168 sites. At week 24, enlicitide achieved a 55.8% placebo-adjusted LDL-C reduction, meeting all primary and key secondary endpoints. The reduction was maintained at 47.6% at week 52.

CORALreef HeFH (Phase 3, JAMA 2026)#

Published in JAMA (PMID 41206969), this trial enrolled 303 adults with heterozygous familial hypercholesterolemia at 59 sites across 17 countries. Enlicitide achieved a 58.2% LDL-C reduction vs 2.6% increase with placebo at week 24.

CORALreef Outcomes (Phase 3, Ongoing)#

A cardiovascular outcomes trial (NCT06008756) enrolling over 19,000 participants is underway to determine whether enlicitide reduces major adverse cardiovascular events (MACE), the definitive test for any lipid-lowering therapy.

Important Considerations#

Enlicitide decanoate is an investigational medication not yet approved by any regulatory authority. Key considerations include:

• Merck expects to submit for FDA approval in early 2026, with a decision potentially in late 2026 or 2027
• Cardiovascular outcomes data from the CORALreef Outcomes trial are not yet available; efficacy on LDL-C is a validated surrogate endpoint but does not replace outcomes data
• The safety profile has been favorable, with adverse event rates comparable to placebo through 52 weeks
• Enlicitide does not replace statins but is intended as add-on therapy for patients not at LDL-C goal
• Long-term effects of sustained oral PCSK9 inhibition beyond 52 weeks require continued evaluation

Key Research Findings#

A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide, published in New England Journal of Medicine (Navar AM et al., 2026; DOI: 10.1056/NEJMoa2511002):

• The study showed a 55.8% placebo-adjusted LDL-C reduction at week 24
• The study showed sustained 47.6% reduction at week 52
• Safety profile was comparable to placebo with no excess adverse events

Efficacy and Safety in Heterozygous Familial Hypercholesterolemia, published in JAMA (Ballantyne CM et al., 2026; PMID: 41206969):

• The study showed a 58.2% LDL-C reduction vs 2.6% increase with placebo
• Nearly 70% of patients achieved both a 50% LDL-C reduction and LDL-C below 70 mg/dL

Related Reading#

• Enlicitide research studies and evidence
• Enlicitide dosing protocols
• Enlicitide side effects profile
• GLP-1 research guide